Market Performance of Neovacs (ALNEV.PA)
Neovacs (ALNEV.PA) closed 23.33 % lower on Thursday, 22 October 2026, at 04:11 AM Central Europe.
- Current price: approximately €0.10 on major exchanges.
- Shares outstanding: 159.1 k.
- Market capitalization: €18.8 k.
- Volume in last 24 h: €20.9 k worth of shares were traded.
- Month‑end performance: down 47.73 % since the previous month’s end.
- 200‑day simple moving average: €7.97.
- 52‑week high: €1,000 (23 October 2025).
- 52‑week low: €0.10 (20 October 2026).
Recent Performance of Related Stocks (last 24 h)
| Ticker | Current price | Daily change | Market cap |
|---|---|---|---|
| Acheter‑louerfr (ALALO.PA) | €0.00 | 0 % | €1.3 k |
| Adomos (ALADO.PA) | €0.18 | 0 % | €1.5 k |
| Toosla Saca (ALTOO.PA) | €0.01 | –66.67 % | €1.4 k |
| Phsc (PHSC.L) | GBX 7.75 | 0 % | GBX 1.1 mn |
| Iconic Labs (ICON.L) | GBX 1.4 | 0 % | GBX 379.7 k |
Company Overview – Neovacs S.A.
- Sector: Biotechnology
- Headquarters: Paris, France
- Founded: 1993
- Website: www.neovacs.fr
- Listing: NYSE Euronext Paris
Product Pipeline
| Product | Development stage | Target indication |
|---|---|---|
| IFNa Kinoid | Phase IIb (clinical trial) | Systemic lupus erythematosus |
| IFNa Kinoid (dermatomyositis) | Phase IIa (clinical trial) | Dermatomyositis |
| IFNa Kinoid (diabetes) | Pre‑clinical | Type 1 diabetes |
| VEGF-Kinoid | Pre‑clinical | Age‑related macular degeneration, solid tumours |
| IL‑4/IL‑13 Kinoid | Pre‑clinical | Allergies |
| VEGF‑Kinoid (colorectal & ovarian cancer) | Pre‑clinical | Collaborative project with Sunnybrook Research Institute |
Neovacs specializes in therapeutic vaccines using proprietary Kinoid technology for chronic autoimmune and inflammatory diseases.
